Yungan Tao

Yungan Tao

Auto-generated profile, based on publicly available information

Yungan Tao

Gustave Roussy

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
ALAnne W. Lee
Anne W. Lee
WNWai Tong Ng
Wai Tong Ng
TLTianzhu Lu
Tianzhu Lu
SPSharon S. Poh
Sharon S. Poh
YAYong Chan Ahn
Yong Chan Ahn
JWJoseph T. Wee
Joseph T. Wee

1 February 2012 in The Lancet Oncology
Verified
Journal Article
Closed access
Jean BourhisJean Bourhis
Jean Bourhis
CSChristian Sire
Christian Sire
PGPierre Graff
Pierre Graff
VGVincent Grégoire
Vincent Grégoire
PMPhilippe Maingon
Philippe Maingon
AAAnne Aupérin
Anne Aupérin

1 October 2007 in Nature Clinical Practice Oncology
Verified
Journal Article
Closed access
YTYungan Tao
Yungan Tao
VPValentina Pinzi
Valentina Pinzi
Jean BourhisJean Bourhis
Jean Bourhis
Eric DeutschEric Deutsch
Eric Deutsch

11 December 2017 in Annals of Oncology
Verified
Journal Article
Closed access
PDF file
MFM. Frikha
M. Frikha
AAA. Auperin
A. Auperin
YTY. Tao
Y. Tao
FEF. Elloumi
F. Elloumi
NTN. Toumi
N. Toumi
Jean BourhisJean Bourhis
Jean Bourhis
Concomitant chemotherapy (CT)–radiotherapy (RT) is a standard of care in locally advanced nasopharyngeal carcinoma (NPC) and a role for induction CT is not established. Patients with locally advanced NPC, WHO type 2 or 3, were randomized to induction TPF plus concomitant cisplatin-RT or concomitant cisplatin-RT alone. The TPF regimen consisted of three cycles of Docetaxel 75 mg/m2 day 1; cisplatin 75 mg/m2 day 1; 5FU 750 mg/m2/day days 1–5. RT consisted of 70 Gy in 7 weeks plus concomitant cisplatin 40 mg/m2 weekly. A total of 83 patients were included in the study. Demographics and tumour characteristics were well balanced between both arms. Most of the patients (95%) in the TPF arm received three cycles of induction CT. The rate of grade 3–4 toxicity and the compliance (NCI-CTCAE v3) during cisplatin-RT were not different between both arms. With a median follow-up of 43.1 months, the 3-year PFS rate was 73.9% in the TPF arm versus 57.2% in the reference arm [hazard ratio (HR) = 0.44; 95% confidence interval (CI): 0.20–0.97, P = 0.042]. Similarly the 3 years overall survival rate was 86.3% in the TPF arm versus 68.9% in the reference arm (HR = 0.40; 95% CI: 0.15–1.04, P = 0.05). In conclusion, several important aspects can be emphasized: the compliance to induction TPF was good and TPF did not compromise the tolerance of the concomitant RT-cisplatin phase. The improved PFS and overall survival rates needs to be confirmed by further trials.

1 November 2018 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
LGLionnel Geoffrois
Lionnel Geoffrois
LMLaurent Martin
Laurent Martin
DRDominique De Raucourt
Dominique De Raucourt
XSXu Shan Sun
Xu Shan Sun
YTYungan Tao
Yungan Tao
Jean BourhisJean Bourhis
Jean Bourhis
Purpose: Both concurrent chemoradiotherapy (CT-RT) and cetuximab radiotherapy (cetux-RT) have been established as the standard of care for the treatment of locally advanced squamous cell carcinoma of the head and neck. It was not known whether the addition of induction chemotherapy before cetux-RT could improve outcomes compared with standard of care CT-RT. Patients and Methods: The current trial was restricted to patients with nonmetastatic N2b, N2c, or N3 squamous cell carcinoma of the head and neck and fit for taxotere, cisplatin, fluorouracil (TPF). Patients were randomly assigned to receive three cycles of TPF followed by cetux-RT versus concurrent carboplatin fluorouracil and RT as recommended in National Comprehensive Cancer Network guidelines. The trial was powered to detect a hazard ratio (HR) of 0.66 in favor of TPF plus cetux-RT for progression-free survival at 2 years. The inclusion of 180 patients per arm was needed to achieve 80% power at a two-sided significance level of .05. Results: Between 2009 and 2013, 370 patients were included. All patients and tumors characteristics were well balanced between arms. There were more cases of grade 3 and 4 neutropenia in the induction arm, and the induction TPF was associated with 6.6% treatment-related deaths. With a median follow-up of 2.8 years, 2-year progression-free survival was not different between both arms (CT-RT, 0.38 v TPF + cetux-RT, 0.36; HR, 0.93 [95% CI, 0.73 to 1.20]; P = .58). HR was 0.98 (95% CI, 0.74 to 1.3; P = .90) for locoregional control and 1.12 (95% CI, 0.86 to 1.46; P = .39) for overall survival. These effects were observed regardless of p16 status. The rate of distant metastases was lower in the TPF arm (HR, 0.54 [95% CI, 0.30 to 0.99]; P = .05). Conclusion: Induction TPF followed by cetux-RT did not improve outcomes compared with CT-RT in a population of patients with advanced cervical lymphadenopathy.

1 December 2015 in Cancer Treatment Reviews
Verified
Journal Article
Closed access
HMHaïtham Mirghani
Haïtham Mirghani
FAFurrat Amen
Furrat Amen
YTYungan Tao
Yungan Tao
Eric DeutschEric Deutsch
Eric Deutsch
ALAntonin Levy
Antonin Levy